Two executives of a Chinese chemical company have been convicted on charges related to the importation of fentanyl precursors and money laundering, as announced by Danielle R. Sassoon, the United States Attorney for the Southern District of New York, and Derek S. Maltz, the Acting Administrator of the U.S. Drug Enforcement Administration (DEA). Qingzhou Wang and Yiyi Chen, associated with HUBEI AMARVEL BIOTECH CO., LTD., faced a two-week trial, resulting in their conviction. Wang was also found guilty of importing a methamphetamine precursor, according to the Southern District of New York's Office of the U.S. Attorney.
In addition to the convictions, law enforcement took down seven websites and seized four cryptocurrency accounts, totaling some $900,000. These were connected to the company’s operations and, were part of an ongoing effort to combat the fentanyl supply chain. Previously, five other websites linked to the chemical manufacturer had been seized in June 2023. Sassoon underscored the defendants' willful endangerment of American lives, emphasizing the message that authorities are vigilant and resolute in their pursuit of illegal fentanyl operations.
The DEA's Acting Administrator Maltz expressed the human toll he has witnessed due to illicit fentanyl, recounting the heartbreak of families who have lost loved ones. He reinforced the agency's commitment to holding those along the fentanyl supply chain accountable, regardless of their global location. The DEA used extensive resources to track and convict these foreign nationals, whose operations have contributed to the opioid crisis in America which claimed over 100,000 lives in the span of a year. According to statements obtained by the U.S. Attorney's Office, Wang and Chen engaged in discussions about supplying ton quantities of the lethal drug precursors.
The investigation revealed that AMARVEL BIOTECH and its executives, willingly did business with individuals they knew were involved in fentanyl production for the U.S. market. Undercover DEA agents, posing as narcotics operators, communicated with the defendants and secured shipments of precursor chemicals to the United States. During these covert exchanges, they discussed the potency and lethal nature of the anticipated fentanyl yield, going as far as meeting with undercover agents in Bangkok to strategize around the supply of precursors for manufacturing even more potent variants of the opioid, as the U.S. Attorney's Office reported.
The company's flagrant online advertising and deceptive measures for shipping illegal chemicals were key aspects of the case. AMARVEL BIOTECH not only marketed precursors as a "Mexico hot sale," but also boasted about evading detection by using misleading packaging, essentially camouflaging drug shipments. In statements obtained by the DEA, the company was found to be targeting areas well-known for drug trafficking, such as the Sinaloa Cartel's hub in Culiacan.
Wang and Chen were convicted of multiple counts, with each facing a substantial prison sentence. The prosecutions were led by Assistant U.S. Attorneys Alexander Li and Kevin Sullivan, with a collective effort from various DEA offices around the world, as well as international law enforcement partnerships.
